Reversal of phenotypes of cellular senescence by pan-mTOR inhibition

Aging

Volumn 8, Issue 2, 2016, Pages 231-244

  Walters, Hannah E ^a   Deneka Hannemann, Sylwia ^a,b   Cox, Lynne S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD BIOMEDICA UK LTD   (United Kingdom)

Author keywords

Aging; AZD8055; Cellular senescence; MTORC1; MTORC2; Rapamycin

Indexed keywords

(5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANTAGONISTS AND INHIBITORS; CELL AGING; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; FIBROBLAST; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOBLOTTING; PHENOTYPE; PHYSIOLOGY; SKIN;

CELL AGING; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; HUMANS; IMMUNOBLOTTING; MICROSCOPY, FLUORESCENCE; MORPHOLINES; PHENOTYPE; SKIN; TOR SERINE-THREONINE KINASES;

EID: 84961198355     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100872     Document Type: Article

References (72)

1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M and Kroemer G. The hallmarks of aging. Cell. 2013; 153: 1194-1217.
2. Herbig U, Ferreira M, Condel L, Carey D and Sedivy JM. Cellular senescence in aging primates. Science. 2006; 311: 1257.
3. Jeyapalan JC, Ferreira M, Sedivy JM and Herbig U. Accumulation of senescent cells in mitotic tissue of aging primates. Mech Aging Dev. 2007; 128: 36-44.
4. van Deursen JM. The role of senescent cells in aging. Nature. 2014; 509: 439-446.
5. Dimri GP et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92: 9363-9367.
6. Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 1994; 211: 90-98.
7. Sato S, et al. Ablation of the p16(INK4a) tumour suppressor reverses aging phenotypes of klotho mice. Nat Commun. 2015; 6: 7035.
8. Quereda V, Martinalbo J, Dubus P, Carnero A and Malumbres M. Genetic cooperation between p21Cip1 and INK4 inhibitors in cellular senescence and tumor suppression. Oncogene. 2007; 26: 7665-7674.
9. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D and Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A. 1996; 93: 13742-13747.
10. Choudhury AR, et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet. 2007; 39: 99-105.
11. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, Kirkland JL and van Deursen JM. Clearance of p16Ink4a-positive senescent cells delays aging-associated disorders. Nature. 2011; 479: 232-236.
12. Rudolph KL, Chang S, Millard M, Schreiber-Agus N and DePinho RA. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science. 2000; 287: 1253-1258.
13. Jaskelioff M, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature. 2010; 469: 102-106.
14. Cox LS and Mason PA. Prospects for rejuvenation of aged tissue by telomerase reactivation. Rejuvenation Res. 2010; 13: 749-754.
15. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW and Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009; 325: 201-204.
16. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460: 392-395.
17. Cox LS and Mattison JA. Increasing longevity through caloric restriction or rapamycin feeding in mammals: common mechanisms for common outcomes? Aging Cell. 2009; 8: 607-13
18. Cox LS. Live fast, die young: new lessons in mammalian longevity. Rejuvenation Res. 2009; 12: 283-288.
19. Vezina C, Kudelski A and Sehgal SN. Rapamycin (AY-22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975; 28: 721-726.
20. Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White DJ and Thiru S. Rapamycin for immunosuppression in organ allografting. Lancet. 1989; 2: 227.
21. Heitman J, Movva NR and Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991; 253: 905-909.
22. Huang K and Fingar DC. Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol. 2014; 36: 79-90.
23. Johnson SC, Sangesland M, Kaeberlein M and Rabinovitch PS. Modulating mTOR in aging and health. Interdiscip Top Gerontol. 2015; 40: 107-127.
24. Johnson SC, Rabinovitch PS and Kaeberlein M. mTOR is a key modulator of aging and age-related disease. Nature. 2013; 493: 338-345.
25. Choo AY, Yoon SO, Kim SG, Roux PP and Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-typespecific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008; 105: 17414-17419.
26. Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ and Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013; 497: 217-223.
27. Yip CK, Murata K, Walz T, Sabatini DM and Kang SA. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell. 2010; 38: 768-774.
28. Benjamin D, Colombi M, Moroni C and Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011; 10: 868-880.
29. Chresta CM, et al. AZD8055 is a potent, selective and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2009; 70: 288-298.
30. Naing A, Aghajanian C, Raymond E, Olmos D, Schwartz G, Oelmann E, Grinsted L, Burke W, Taylor R, Kaye S, Kurzrock R and Banerji U. Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. Br J Cancer. 2012; 107: 1093-1099.
31. Kim YM, Byun HO, Jee BA, Cho H, Seo YH, Kim YS, Park MH, Chung HY, Woo HG and Yoon G. Implications of time-series gene expression profiles of replicative senescence. Aging Cell. 2013; 12: 622-634.
32. Yoon YS, Yoon DS, Lim IK, Yoon SH, Chung HY, Rojo M, Malka F, Jou MJ, Martinou JC and Yoon G. Formation of elongated giant mitochondria in DFO-induced cellular senescence: involvement of enhanced fusion process through modulation of Fis1. J Cell Physiol. 2006; 209: 468-480.
33. Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D and Collins FS. Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med. 2011; 3: 89ra58.
34. Noda T and Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem. 1998; 273: 3963-3966.
35. Kim J, Kundu M, Viollet B and Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011; 13: 132-141.
36. Vichai V and Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006; 1: 1112-1116.
37. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N and Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998; 12: 502-513.
38. Campisi J. Senescent cells, tumor suppression and organismal aging: good citizens, bad neighbors. Cell. 2005; 120: 513-522.
39. Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, Hejtmancik JF, Nadon N, Strong R, Wood LK, Woodward MA and Miller RA. Rapamycin slows aging in mice. Aging Cell. 2012; 11: 675-682.
40. Alzheimer's Disease International and World Health Organisation. Dementia: a public health priority. 2012; ISBN 978 4 156445 8
41. Lin AL, et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J Cereb Blood Flow Metab. 2013; 33: 1412-1421.
42. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R and Galvan V Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One. 2010; 5: e9979.
43. Richardson A, Galvan V, Lin AL and Oddo S. How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story. Exp Gerontol. 2014; 68: 51-8
44. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S and Greene LA. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci. 2010; 30: 1166-1175.
45. Chong ZZ, Shang YC, Wang S and Maiese K. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol. 2012; 99: 128-148.
46. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A and Oddo S, Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. Aging Cell. 2012; 11: 326-335.
47. Ferrer IR, Wagener ME, Robertson JM, Turner AP, Araki K, Ahmed R, Kirk AD, Larsen CP and Ford ML, Cutting edge: Rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol. 2010; 185: 2004-2008.
48. Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, Lonetto MA, Maecker HT, Kovarik J, Carson S, Glass DJ and Klickstein LB, mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014; 6: 268ra179.
49. Goldberg EL, Smithey MJ, Lutes LK, Uhrlaub JL and Nikolich-Zugich J, Immune memory-boosting dose of rapamycin impairs macrophage vesicle acidification and curtails glycolysis in effector CD8 cells, impairing defense against acute infections. J Immunol. 2014; 193: 757-763.
50. Jiang Q, Weiss JM, Back T, Chan T, Ortaldo JR, Guichard S and Wiltrout RH, mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. Cancer Res. 2011; 71: 4074-4084.
51. Puleston DJ, Zhang H, Powell TJ, Lipina E, Sims S, Panse I, Watson AS, Cerundolo V, Townsend AR, Klenerman P and Simon AK, Autophagy is a critical regulator of memory CD8(+) T cell formation. Elife. 2014; 3.
52. Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL and Pass M, Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. Bioorg Med Chem Lett. 2013; 23: 1212-1216.
53. Vellai T, Takacs-Vellai K, Sass M and Klionsky DJ, The regulation of aging: does autophagy underlie longevity? Trends Cell Biol. 2009; 19: 487-494.
54. He C and Klionsky DJ, Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009; 43: 67-93.
55. Huo Y, Iadevaia V, Yao Z, Kelly I, Cosulich S, Guichard S, Foster LJ and Proud CG, Stable isotope-labelling analysis of the impact of inhibition of the mammalian target of rapamycin on protein synthesis. Biochem J. 2012; 444: 141-151.
56. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS and Sabatini DM, A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 2012; 485: 109-113.
57. Levina EM, Kharitonova MA, Rovensky YA and Vasiliev JM, Cytoskeletal control of fibroblast length: experiments with linear strips of substrate. J Cell Sci. 2001; 114: 4335-4341.
58. Blattler SM, Cunningham JT, Verdeguer F, Chim H, Haas W, Liu H, Romanino K, Ruegg MA, Gygi SP, Shi Y and Puigserver P, Yin Yang 1 deficiency in skeletal muscle protects against rapamycin-induced diabetic-like symptoms through activation of insulin/IGF signaling. Cell Metab. 2012; 15: 505-517.
59. Wan X, Harkavy B, Shen N, Grohar P and Helman LJ, Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2007; 26: 1932-1940.
60. Josselyn SA and Frankland PW, mTORC2: actin on your memory. Nat Neurosci. 2013; 16: 379-380.
61. Ding Z, et al., Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell. 2012; 148: 896-907.
62. Gomes AP, et al., Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013; 155: 1624-1638.
63. Saunders LR and Verdin E, Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007; 26: 5489-5504.
64. Cruickshanks HA, et al., Senescent cells harbour features of the cancer epigenome. Nat Cell Biol. 2013; 15: 1495-1506.
65. Davis T, Bachler MA, Wyllie FS, Bagley MC and Kipling D, Evaluating the role of p38 MAP kinase in growth of Werner syndrome fibroblasts. Ann N Y Acad Sci. 2010; 1197: 45-48.
66. Pospelova TV, Leontieva OV, Bykova TV, Zubova SG, Pospelov VA and Blagosklonny MV, Suppression of replicative senescence by rapamycin in rodent embryonic cells. Cell Cycle. 2012; 11: 2402-2407.
67. Brandhorst S, et al. A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance and Healthspan. Cell Metabolism. 2015; 22:86-99.
68. Cox LS, Midgley CA and Lane DP, Xenopus p53 is biochemically similar to the human tumour suppressor protein p53 and is induced upon DNA damage in somatic cells. Oncogene. 1994; 9: 2951-2959.
69. Warbrick E, Lane DP, Glover DM and Cox LS, A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. Curr Biol. 1995; 5: 275-282.
70. Laberge RM, Sun Y, Orjalo AV, Patil CK, Freund A, Zhou L, Curran SC, Davalos AR, Wilson-Edell KA, Liu S, Limbad C, Demaria M, Li P, Hubbard GB, Ikeno Y, Javors M, Desprez PY, Benz CC, Kapahi P, Nelson PS and Campisi J, MTOR regulates the protumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol. 2015;17:1049-1061.
71. Goukassian D1, Gad F, Yaar M, Eller MS, Nehal US, and Gilchrest BA, Mechanisms and implications of the age-associated decrease in DNA repair capacity. FASEB J. 2000; 14:1325-1334.
72. Blagosklonny MV, Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging (Albany, NY). 2012; 4:159-165.